Early Stage Venture Investing
Midwest Value Orientation
Exceptional Capital Returns
The VCapital Advantage
World-class due diligence and our team’s selection aptitude combine to bring exceptional venture capital opportunities online to accredited investors. Reasonable fees and low minimums make it easy to diversify your portfolio with exciting (and potentially world-changing) institutional-quality deals.
Based in Chicago, we know what drives business success in the heartland and beyond.
We seek opportunities to make a difference to the world and to your bottom line.
Early stage investors, we concentrate on the underserved $500k-$5M range.
Deep operating experience enables us to guide our funded entrepreneurs to successful outcomes.
Our industry connections, expansive network, and 30-year track record gives us access to unique deals.
We only invest in opportunities that pass our rigorous screening and vetting process.
Invest with VCapital
Select and invest in the best opportunities for your portfolio using our online platform.
We offer two options for the management fee.
- a one-time fee equal to 8% of the undersigned’s capital contribution to the Company.
- an annual fee equal to 2% per annum of the undersigned’s capital contribution to the Company.
Synap makes and sells software primarily for account management and customer success teams. Its flagship product is designed specifically for post-sales engagement, helping teams to build, collaborate, and execute on their plans to grow customer relationships.
simMachines is changing the Machine Learning (ML) paradigm with its proprietary similarity-based technology, which is the only ML technology capable of providing transparency to the factors driving the prediction (what is called Predictions with The WHY™) at the speed and scale required for enterprise use.
Our team invested $2.3 million in Intensity Therapeutics and raised an additional $1.5 million for the Company. Intensity Therapeutics is pioneering a new field of cancer treatment – in situ vaccination – to eliminate metastatic disease and prevent cancer from recurring.
Cleversafe is the marketplace leader in dispersed storage technology for unstructured data in the petabyte-plus range. Our team raised $4.5 million through BVC. The company was purchased by IBM in Oct. 2015 for $1.3 billion.
Opportunities Currently in Due Diligence
RedFin for commercial real estate. This firm is disrupting the tenant rep space and has a management team with several previous successful exits.
One of the founders of Lasik is leading a team that has developed a shunt for glaucoma, the leading cause of blindness.
The all-in-one tool for all tablets and cell phones which turns them into your own personal recording and video device. This company already has significant revenue and is sold world-wide.
World renowned physician, Dr. Jon Odorico, MD, FACS from the University of Wisconsin, is developing a way to use a patient's own stem cells to fight Diabetes.
Through the use of their patented oxygen therapeutic, NuvOx received its IND for phase II in GBM, is currently in Phase I in stroke, and is about to begin Phase I in Sickle Cell. There are even more applications on which their therapeutic may be used, and most of their studies have been funded from non-dilutive grants.
Stealth company working on a unique and promising approach to quantum computing.
Become a Founding Investor
For a limited time, you may also join VCapital as a founding investor. You will have priority access to our dealflow, the opportunity to connect with portfolio company management teams, and participate in the proceeds in all successful deals, now and in the future!Invest and Join Now
Register now to see full deal information, get dealflow updates, or make an investment.